Arab Israeli Conflict
Middle East News
Hi Tech News
Mylan rejected Teva's $41 billion bid earlier this week.
Acquisition would create leading company with potential to transform global market for generics.
Teva sought stay of lower court ruling that favored developers of generic versions of its top selling multiple sclerosis drug.
Israeli media assesses that at some 300 employees would lose their jobs.
By SHARON UDASIN
ZIM CEO Eli Glickman pays homage to the CEOs of Teva Israel, Mehadrin, Keter Plastic, and other prominent Israeli companies
By JPOST.COM STAFF
Why the pharmaceutical giant needs to be bailed out
By SHLOMO MAITAL
Teva Pharmaceuticals, Israel’s biggest
company, has seen its share price
halved as generics eat at its profits,
and leveraged buyouts have left it
burdened with huge debts.
In the battle of the giants it is Israel’s Teva that is the heavyweight, and the American company, the lightweight.
It is very difficult to do business in Israel, especially for a start-up seeking to grow independently.
Erez Vigodman, the new CEO of Teva, Israel’s premier global company, has to work fast to pull the conglomerate out of crisis.
Beersheba residents now have a bevy of food-buying options, including three new grocery chain stores as well as revamped older shops.
By YOCHEVED MIRIAM RUSSO
We need remind ourselves that all instruments of power, governmental and non-governmental, are never totally free of weaknesses.
By YISRAEL MEDAD AND ELI POLLAK
Over the past two years, Teva lost $57b. of value, leaving it with a remaining market value of $19b. It owes about $35b.
By GLENN YAGO
Please insert a valid email address